Fig. 1

Rate ratio of participants by nasal Aβ42 levels as quartiles. Proportions of participants in each nasal Aβ42 quartile group—Q1 (blue), Q2 (green), Q3 (orange), and Q4 (red)—are shown according to (A) clinical diagnosis, (B) Clinical Dementia Rating (CDR), (C) Global Deterioration Scale (GDS), and (D) Mini-Mental State Examination (MMSE) categories. Group sizes for clinical diagnosis (A) are: CU (n = 32), Preclinical (n = 29), MCI (n = 73), and AD (n = 27). Group sizes for CDR (B) are: CU (n = 42), MCI (n = 95), and AD (n = 24). Group sizes for GDS (C) are: CU (n = 6), MCI (n = 116), and AD (n = 39). Group sizes for MMSE (D) are: CU (n = 65), MCI (n = 40), and AD (n = 56). Aβ, amyloid beta; CDR, Clinical Dementia Rate; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CU, cognitively unimpaired; GDS, Global Deterioration Scale; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination.